Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM

Summary

gpASIT+TM product is based on highly purified allergen fragments obtained from grass pollen. The purpose of this clinical trial is to confirm the safety, clinical tolerability and immunogenicity of increasing doses of gpASIT+TM administered subcutaneously to patients with grass pollen-induced allergic rhinoconjunctivitis, and to determine the maximal tolerated dose of gpASIT+TM .

Timeline

Start

2013-08

Primary completion

2013-12

Completion

2013-12

Drugs

Indications